The HHS said center directors deserve to be supported by managers aligned with aggressive goals “to expeditiously advance therapeutics for rare diseases using the gold standard of science.” ...

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...